CYP2D6 pharmacogenetics and risperidone : reflections after 25 years of research
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 21(2020), 16 vom: 01. Nov., Seite 1139-1144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Leon, Jose [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.08.2021 Date Revised 26.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2020-0115 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316242764 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316242764 | ||
| 003 | DE-627 | ||
| 005 | 20231225160651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2020-0115 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316242764 | ||
| 035 | |a (NLM)33054667 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Leon, Jose |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CYP2D6 pharmacogenetics and risperidone |b reflections after 25 years of research |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.08.2021 | ||
| 500 | |a Date Revised 26.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Historical Article | |
| 650 | 4 | |a CYP3A4 | |
| 650 | 4 | |a phenotype | |
| 650 | 4 | |a drug interactions | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a renal insufficiency | |
| 650 | 4 | |a risperidone blood | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP2D6 |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Risperidone |2 NLM | |
| 650 | 7 | |a L6UH7ZF8HC |2 NLM | |
| 700 | 1 | |a Schoretsanitis, Georgios |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 21(2020), 16 vom: 01. Nov., Seite 1139-1144 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:16 |g day:01 |g month:11 |g pages:1139-1144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2020-0115 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 16 |b 01 |c 11 |h 1139-1144 | ||